- cafead Jan 20, 2023 at 10:42: AM
via The next big test of Daiichi Sankyo’s antibody-drug conjugation prowess, which spawned Enhertu and a multi-billion dollar alliance with Astrazeneca, is approaching. Datopotamab deruxtecan, an ADC against Trop2, will shortly yield data from its first phase 3 study, Tropion-Lung01, and if favourable this will lead to a first-half regulatory filing.
article source
article source